UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

Form 10-Q

 

(Mark  (Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 
 

For the quarterly period ended September 30, 2021March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 
 

For the transition period from ____ to _____

Commission file number: 1-16525

 

CVD EQUIPMENT CORPORATION

 

(Name of Registrant in Its Charter)

 

New York

11-2621692

State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer Identification No.)

355 South Technology Drive

Central Islip, New York 11722

(Address of principal executive offices)

 

(631) 981-7081
(Registrants Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

CVV

NASDAQ Capital Market

 

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑  No ☐No☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑  No ☐No☐

 

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act).

 

Large accelerated filer  ☐Accelerated filer  ☐ 
Non-accelerated filer     ☑Smaller reporting company       ☑Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 Yes ☐   No ☑

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 6,687,4386,728,938 shares of Common Stock, $0.01 par value at November 8, 2021.May 9, 2022.

 

 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

 

Index

 

Part I - Financial Information 

Item 1 – Condensed Consolidated Financial Statements (Unaudited)

 
  

Condensed Consolidated Balance Sheets at September 30, 2021March 31, 2022 and December 31, 20202021

3

  

Condensed Consolidated Statements of Operations for the three and nine months ended September 30,March 31, 2022 and 2021 and 2020

4

  

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30,March 31, 2022 and 2021 and 2020

5

  

Condensed Consolidated Statements of Cash Flows for the ninethree months ended September 30,March 31, 2022 and 2021 and 2020

6

  

Notes to Condensed Consolidated Financial Statements

7

  

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations

2219

Item 3 – Quantitative and Qualitative Disclosures About Market Risk

3227

Item 4 – Controls and Procedures

3227

  

Part II - Other Information

 
  

Item 1 – Legal Proceedings

3328

Item 1A-Risk Factors

3328

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

3428

Item 3 – Defaults Upon Senior Securities

3428

Item 4 – Mine Safety Disclosures

3428

Item 5 – Other Information

3428

Item 6 – Exhibits

3428

  

Signatures

3530

  

Exhibit Index

3631

 

 

2

 

 

PART 1 – FINANCIAL INFORMATION

Item 1 – Financial Statements

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

 

 (Unaudited)    (Unaudited)   
 

September 30, 2021

  

December 31, 2020

  

March 31, 2022

  

December 31, 2021

 

ASSETS

        

Current Assets

  

Cash and cash equivalents

 $17,446,404  $7,699,335  $13,270,853  $16,651,371 

Accounts receivable, net

 1,891,913  1,047,728  1,498,183  1,446,354 

Contract assets

 1,628,168  494,281  2,717,823  2,538,373 

Inventories, net

 1,465,744  1,123,839  1,737,901  1,225,015 

Taxes Receivable

 715,599  715,599  0  715,599 

Other current assets

  207,841   709,175   384,286   493,788 
 
  

Total Current Assets

 23,355,669  11,789,957  19,609,046  23,070,500 
  

Property, plant and equipment, net

 12,368,838  28,843,563  12,196,745  12,261,321 

Intangible assets, net

 209,851  288,657  191,316  182,838 

Other assets

  23,318   13,748   9,570   9,570 

Total Assets

 $35,957,676  $40,935,925  $32,006,677  $35,524,229 
  
  

LIABILITIES AND STOCKHOLDERS EQUITY

        

Current Liabilities

  

Accounts payable

 $854,159  $817,933  $1,178,206  $1,161,381 

Accrued expenses

 1,476,871  1,409,039  1,820,341  1,758,939 

Current maturities of long-term debt

 1,840,508  690,667  0  1,765,508 

Contract Liabilities

  1,504,345   786,657   720,385   1,650,426 

Total Current Liabilities

  5,675,883   3,704,296   3,718,932   6,336,254 
  

Long-term debt, net of current portion

  0   13,106,057 
 

Total Liabilities

  5,675,883   16,810,353   3,718,932   6,336,254 
  

Commitments and contingencies (see note 12)

       
 
  

Stockholders’ Equity:

  

Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,687,438 at September 30, 2021 and 6,678,698 at December 31, 2020

 66,874  66,786 

Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,728,938 at March 31, 2022 and 6,723,438 at December 31, 2021

 67,289  67,234 

Additional paid-in capital

 27,179,538  26,961,684  27,374,209  27,277,154 

Retained earnings (accumulated deficit)

  3,035,381   (2,902,898)

Retained earnings

  846,247   1,843,587 

Total Stockholders’ Equity

  30,281,793   24,125,572   28,287,745   29,187,975 
  

Total Liabilities and Stockholders’ Equity

 $35,957,676  $40,935,925  $32,006,677  $35,524,229 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

3

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

 

 

Three Months Ended

 

Nine Months Ended

  

Three Months Ended

 
 

September 30,

 

September 30,

  

MARCH 31,

 
 

2021

  

2020

  

2021

  

2020

  

2022

  

2021

 
  

Revenue

 $4,329,459  $3,993,204  $11,729,727  $13,748,448  $4,655,727  $3,365,860 
  

Cost of revenue

  3,595,244   3,557,413   9,831,270   10,775,618   3,886,176   2,921,554 
  

Gross profit

  734,215   435,791   1,898,457   2,972,830   769,551   444,306 
  

Operating expenses

  

Research and development

 138,064  90,227  367,008  300,162 

Engineering, research and development

 310,207  310,954 

Selling and shipping

 220,745  142,306  574,476  439,346  272,679  135,755 

General and administrative

  1,297,730   1,595,911   4,581,008   4,650,067   1,192,653   1,616,384 
  

Total operating expenses

  1,656,539   1,828,444   5,522,492   5,389,575   1,775,539   2,063,093 
  

Operating loss

  (922,324)  (1,392,653)  (3,624,035)  (2,416,745)  (1,005,988)  (1,618,787)
  

Other income (expense):

  

Interest income

 1,776  30,348  3,402  60,728  18,282  1,223 

Interest expense

 (35,973) (104,041) (250,194) (336,107) (9,634) (107,221)

Gain on Sale of Building

 6,894,109  0  6,894,109  0 

Gain on Debt Extinguishment

 0  0  2,443,418  0 

Other Income

  63,143   174,705   499,970   394,938   0   219,235 

Total other income, net

  6,923,055   101,012   9,590,705   119,559   8,648   113,237 
  

Income (loss) before income tax

 6,000,731  (1,291,641) 5,966,670  (2,297,186)

Loss before income tax

 (997,340) (1,505,550)
  

Income tax expense (benefit)

  27,327   0   28,391   (1,529,595)

Income tax expense

  0   0 
  

Net income (loss)

 $5,973,404  $(1,291,641) $5,938,279  $(767,591)

Net loss

 $(997,340) $(1,505,550)
  

Basic loss per common share

 $(0.15) $(0.23)

Diluted loss per common share

 $(0.15) $(0.23)
  

Basic income (loss) per common share

 $0.89  $(0.19) $0.89  $(0.12)

Diluted income (loss) per common share

 $0.89  $(0.19) $0.89  $(0.12)

Weighted average common shares Outstanding-basic

  6,725,042   6,680,130 
  
Weighted average common shares                

Outstanding-basic

  6,685,599   6,640,228   6,683,407   6,633,694 
 

Weighted average common shares

 

Outstanding-diluted

  6,707,883   6,640,228   6,691,813   6,633,694 

Weighted average common shares Outstanding-diluted

  6,725,042   6,680,130 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

4

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

 

Three months ended September 30, 2021 and 2020

                 
  

Common stock

             
  

Shares

  

Par

Value

  

Additional

paid-in

Capital

  

Retained

Earnings/ (Accumulated deficit)

  

Total

 
                     

Balance at July 1, 2021

  6,684,281  $66,842  $27,074,079  $(2,938,023) $24,202,898 

Net income

  -   0   0   5,973,404   5,973,404 

Share-Based Compensation

  3,157   32   105,459   0   105,491 

Balance at September 30, 2021

  6,687,438  $66,874  $27,179,538  $3,035,381  $30,281,793 
                     

Balance at July 1, 2020

  6,639,685  $66,396  $26,860,747  $3,696,104   30,623,247 

Net loss

  -   0   0   (1,291,641)  (1,291,641)

Share-Based Compensation

  1,250   13   58,749   0   58,762 

Balance at September 30, 2020

  6,640,935  $66,409  $26,919,496  $2,404,463  $29,390,368 

Nine months ended September 30, 2021 and 2020

                 
  

Common stock

             
  

Shares

  

Par

Value

  

Additional

paid-in

Capital

  

Retained

Earnings/ (Accumulated deficit)

  

Total

 
                     

Balance at January 1, 2021

  6,678,698  $66,786  $26,961,684  $(2,902,898) $24,125,572 

Net income

  -   0   0   5,938,279   5,938,279 

Share-Based Compensation

  8,740   88   217,854   0   217,942 

Balance at September 30, 2021

  6,687,438  $66,874  $27,179,538  $3,035,381  $30,281,793 
                     

Balance at January 1, 2020

  6,623,793  $66,237  $26,719,554  $3,172,054  $29,957,845 

Net loss

  -   0   0   (767,591)  (767,591)

Share-Based Compensation

  17,142   172   199,942   0   200,114 

Balance at September 30, 2020

  6,640,935  $66,409  $26,919,496  $2,404,463  $29,390,368 

Three months ended March 31, 2022 and 2021

             
  

Common stock

             
           Retained    
  

Shares

  

Par Value

  

Additional

paid-in

Capital

  

Earnings/

(Accumulated

deficit)

  

Total

 
                     

Balance at January 1, 2022

  6,723,438  $67,234  $27,277,154  $1,843,587  $29,187,975 

Net loss

  -   -   -   (997,340)  (997,340)

Stock-Based Compensation

  5,500   55   97,055   -   97,110 

Balance at March 31, 2022

  6,728,938  $67,289  $27,374,209  $846,247  $28,287,745 
                     

Balance at January 1, 2021

  6,678,698  $66,786  $26,961,684  $(2,902,898)  24,125,572 

Net loss

  -   0   0   (1,505,550)  (1,505,550)

Stock-Based Compensation

  5,583   56   50,317   -   50,373 

Balance at March 31, 2021

  6,684,281  $66,842  $27,012,001  $(4,408,448) $22,670,395 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

5

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

Nine Months Ended

  

Three Months Ended

 
 

September 30,

  

March 31,

 
 

2021

  

2020

  

2022

  

2021

 

Cash flows from operating activities:

  

Net income (loss)

 $5,938,279  $(767,591)

Adjustments to reconcile net income (loss) to net cash (used in) operating activities

 

Gain on sale of building

 (6,894,109) 0 

Gain on Debt Extinguishment

 (2,443,418) 0 

Net loss

 $(997,340) $(1,505,550)

Adjustments to reconcile net loss to net cash used in operating activities

 

Stock-based compensation

 217,942  200,114  97,110  50,373 

Depreciation and amortization

 585,082  1,023,757  250,949  255,644 

Bad debt expense

 0  120,160 

(Increase)/decrease in operating assets

  

Accounts receivable

 (844,185) 752,463  (51,829) 228,699 

Contract assets

 (1,133,887) (480,889) (179,450) (533,007)

Inventories

 (341,905) 264,978  (512,886) (216,160)

Tax receivable

 0  (713,027) 715,599  0 

Other current assets

 491,764  315,649  109,244  251,987 

Increase/(decrease) in operating liabilities

  

Accounts payable

 36,226  (94,994) 16,825  (314,625)

Accrued expenses

 95,281  (397,546) 61,402  264,123 

Contract liabilities

 717,688  (1,411,578) (930,041) (53,150)
          

Total adjustments

  (9,513,521)  (420,913)  (423,077)  (66,116)

Net cash used in operating activities

  (3,575,242)  (1,188,504)  (1,420,417)  (1,571,666)
  

Cash flows from investing activities:

  

Net proceeds from sale of building

 23,075,477  0 

Net proceeds from sale of assets

 10,000  0 

Patents

 (27,540) 0 

Capital expenditures

  (212,920)  (1,202,899)  (177,053)  (26,744)

Net cash provided by (used in) investing activities

  22,862,557   (1,202,899)

Net cash used in investing activities

  (194,593)  (26,744)
  

Cash flows from financing activities

  

Proceeds from Payroll Protection Plan Loan

 0  2,415,970 
 

Payments of long-term debt

  (9,540,246)  (501,323)  (1,765,508)  (171,562)

Net cash (used in) provided by financing activities

  (9,540,246)  1,914,647 

Net cash used in financing activities

  (1,765,508)  (171,562)
  

Net increase (decrease) in cash and cash equivalents

 9,747,069  (476,756)

Net decrease in cash and cash equivalents

 (3,380,518) (1,769,972)
  

Cash and cash equivalents at beginning of period

  7,699,335   8,664,253   16,651,371   7,699,335 
  

Cash and cash equivalents at end of period

 $17,446,404  $8,187,497  $13,270,853  $5,929,363 
  

Supplemental disclosure of cash flow information:

  

Income taxes paid

 $28,391  $0  $0  $0 

Interest paid

 $250,194  $336,107  $8,953  $106,547 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

6

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

 

NOTE 1:         

 

BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements for CVD Equipment Corporation and Subsidiaries (collectively “the Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. They do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary in order to make the interim financials not misleading have been included and all such adjustments are of a normal recurring nature. The operating results for the three and ninemonths ended September 30, 2021March 31, 2022 are not necessarily indicative of the results that can be expected for the year ending December 31, 2021.2022.

 

The condensed consolidated balance sheet as of December 31, 20202021 has been derived from the audited consolidated financial statements at such date, as filed on Form 10-K with the SEC on March 31, 2021,2022, but does not contain all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with that report.

 

All material intercompany balances and transactions have been eliminated in consolidation. In addition, certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net income.

 

BUSINESS DEVELOPMENTS

In January 2021, the Company’s Board of Directors concluded that a change in the Company’s business strategy and direction was necessary and appointed Emmanuel Lakios as President and Chief Executive Officer (previously our Vice-President- Sales and Marketing) to, among other things, evaluate the Company’s business strategy and operations. Based on this evaluation, due to the continuing losses and significant investments required to continue in the Materials business, the Board concluded that our primary focus should be on the core equipment business and that the Materials Business strategy should be revised, with some of its current element’s potentially minimized or ceased.  Based upon an analysis, including forecasted continued losses and negative cash flows for the Tantaline product line, the Company has implemented plans to eliminate further investment in our Tantaline product line. In addition, we recorded an impairment charge of $3.6 million during the fourth quarter and year ended December 31, 2020, related to Tantaline long lived assets. Further, the Company continues to monitor its costs and has and will continue to take actions to mitigate expenses in the future to align them with anticipated revenue levels.

7

NOTE 1: (continued)

During February 2021, in order to increase the Company’s liquidity and to provide necessary working capital to support the Company’s on-going business and operations, the Board decided to sell its facility located at 555 North Research Place, Central Islip, NY (the “555 Building”). Management determined the 555 Building was not needed for its on-going business operations and concluded that any remaining elements of the Materials Business could be consolidated into its remaining facility in Central Islip (the “355 Building”), which it believes can accommodate any needs for its growth for the foreseeable future. In April 2021, the Company completed the move of its United States Tantaline equipment to the 355 Building, while the MesoScribe consolidation into the 355 Building was completed during Q32021. All functions of the Tantaline product line have been consolidated into the Denmark facility and, the expenses related to Tantaline operations in the United States have ceased.

On March 29, 2021, the Company entered into an agreement with Steel K, LLC for the sale of the 555 Building, and on July 26, 2021 the Company closed on the sale of the 555 Building. The sale price was $24,360,000, subject to adjustment for apportionments, adjustments and credits. A portion of the sale proceeds were used to satisfy the existing mortgage debt on the 555 Building, including interest and fees, in the amount of $9,352,719, as well as various costs related to the closing of the transaction. The Company recognized a gain on the sale of the building in the amount of $6,894,109 and received approximately $14,000,000 in net proceeds (see Note 13).

 

NOTE 2:         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Revenue Recognition

 

The Company designs, manufactures and sells custom chemical vapor deposition equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within three to eighteen months from commencement of order acceptance. The Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations, typically within three months to eighteen months.

obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work in process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated.

 

8

NOTE 2:         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue Recognition (continued)

“Contract assets,” include unbilled amounts typically resulting from system sales under contracts and revenue recognized exceeds the amount billed to the customer. The amount may not exceed their estimated net realizable value. Contract assets are classified as current based on our contract operating cycle.

 

“Contract liabilities,” include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments during the manufacturing cycle. Contract liabilities are classified as current based on our contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period.

 

For outrightnon-system sales of products, the point in time revenue is recognized when control of the promised products or services is transferred to ourthe Company’s customers, in an amount that reflects the consideration we expectthe Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers”.

Recent Accounting Standards

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. On November 15, 2019, the FASB delayed the effective date for smaller reporting companies. The amendments in this update are now effective for fiscal years beginning after December 15, 2022 and interim periods within those annual periods. Management is currently evaluating the effect of this update on the Company’s consolidated financial statements and currently believes it willshould not have a material impact.

 

98

 

NOTE 2:         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Recent Accounting Standards (continued)

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of its financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 

 

NOTE 3:         CONCENTRATION OF CREDIT RISK

 

Cash and cash equivalents

 

The Company had cash and cash equivalents of $17.4$13.3 million and $7.7$16.7 million at September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively. The Company invests excess cash in U.S. treasury bills, certificates of deposit or money marketdeposit accounts, all with original maturities of less than three months. Cash equivalents were $7.0 million at September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount at risk at September 30, 2021March 31, 2022 and December 31, 20202021 was $9,294,000$5,411,000 and $5,822,000,$8,613,000, respectively.

 

Sales concentration

 

Revenue from a single customer in any one period can exceed 10% of our total revenues. During the three months ended September 30, 2021,March 31, 2022, 2three customers exceeded 10% of revenues, representing 15.6%14.3%, 13.3% and 11.8%11.6% of revenues, and during the ninethree months ended September 30,March 31, 2021 2 customersone customer exceeded 10%, representing 12.0% and 11.7%30.7% of revenues. During the three months ended September 30, 2020, 2 customers exceeded 10%, representing 13.5% and 12.5% of revenues, and during the nine months ended September 30, 2020, 3 customers exceeded 10% of revenues, representing 21.0%, 12.8% and 12.0% of revenues.

 

Accounts receivable

 

The Company sells products and services to various companies across several industries in the ordinary course of business. The Company performs ongoing credit evaluations to assess the probability of accounts receivable collection based on a number of factors, including past transaction experience, evaluation of their credit history and review of the invoicing terms of the contract to determine the financial strength of its customers. The Company also maintains allowances for anticipated losses. At September 30, 2021,March 31, 2022, 1 customer exceeded 10% of the accounts receivable balance representing 28.7%, and at December 31, 2020 2four customers exceeded 10% of the accounts receivable balance representing 35.0%58.1%, and at December 31, 2021 two customers exceeded 10% of the accounts receivable balance, representing 50.0% of the accounts receivable balance.

 

109

 
 

NOTE 4:         REVENUE DISAGGREGATION

 

The following table represents a disaggregation of revenue for the three and ninemonths ended September 30, 2021March 31, 2022 and 20202021 (in thousands):

 

 

Three Month's Ending September 30, 2021

  

Three Month's Ending March 31, 2022

 
        
 

Over time

 

Point in time

 

Total

  

Over time

 

Point in time

 

Total

 

Aerospace

 $0  $574  $574  $0  $705  $705 

Energy, storage and transmission

 $899  $7  $906 

Industrial

 $1,551  $1,205  $2,756  $997  $872  $1,869 

Research

 $612  $388  $1,000  $706  $470  $1,176 

Total

 $2,163  $2,167  $4,330  $2,602  $2,054  $4,656 

 

  

Three Month's Ending March 31, 2021

 
             
  

Over time

  

Point in time

  

Total

 

Aerospace

 $189  $526  $715 

Energy, storage and transmission

 $0  $0  $0 

Industrial

 $1,369  $675  $2,044 

Research

 $187  $420  $607 

Total

 $1,745  $1,621  $3,366 

 

  

Three Month's Ending September 30, 2020

 
             
  

Over time

  

Point in time

  

Total

 

Aerospace

 $181  $1,252  $1,433 

Industrial

 $322  $1,346  $1,668 

Research

 $582  $310  $892 

Total

 $1,085  $2,908  $3,993 

  

Nine Month's Ending September 30, 2021

 
             
  

Over time

  

Point in time

  

Total

 

Aerospace

 $386  $1,677  $2,063 

Industrial

 $4,147  $3,173  $7,320 

Research

 $1,164  $1,183  $2,347 

Total

 $5,697  $6,033  $11,730 

  

Nine Month's Ending September 30, 2020

 
             
  

Over time

  

Point in time

  

Total

 

Aerospace

 $1,480  $5,136  $6,616 

Industrial

 $708  $2,830  $3,538 

Research

 $1,671  $1,923  $3,594 

Total

 $3,859  $9,889  $13,748 

11

NOTE 4:         REVENUE DISAGGREGATION (continued)

The Company has unrecognized contract revenue of approximately $5.7$6.2 million at September 30, 2021,March 31, 2022, which it expects to recognize as revenue within the next twelve months.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated statements of operations.

10

NOTE 4:         REVENUE DISAGGREGATION (continued)

 

Contract Assets and Liabilities

 

Contract assets consist of (i) retainage which representrepresents the earned, but unbilled, portion for which payment is deferred by the customer until certain contractual milestones are met; and (ii) unbilled receivables which represent revenue that has been recognized in advance of billing the customer, which is common for long-term contracts. Contract liabilities consist of customer advances and billings in excess of revenue recognized.

 

During the ninethree months ended September 30, 2021March 31, 2022 and 2020,2021, the increase in contract assets of approximately $1.1$.2 million and $.5 million, respectively, was the result of work performed in excess of billings which are based upon project milestones.

 

Contract assets and contract liabilities on input method type contracts in progress are summarized as follows:

 

 

2021

  

2022

 

Costs incurred on contracts in progress

 $5,762,058  $6,878,958 

Estimated earnings

  3,868,499   4,792,589 
 9,630,557  11,671,547 

Billings to date

  (9,168,780)  (9,510,318)
 $461,777  $2,161,229 

Deferred revenue related to non-systems contracts

  (337,954)  (163,791)
  123,823   1,997,438 

Included in accompanying balance sheets

    

Under the following captions:

    

Contract assets

 $1,628,168  $2,717,823 

Contract liabilities

 $(1,504,345) $(720,385)

 

12

 

NOTE 5:          INVENTORIES, NET

 

Inventories consist of:

        
  

September 30,

2021

  

December 31,

2020

 
         

Raw materials

 $1,168,237  $928,221 

Work-in-process

  297,507   195,618 

Inventories

 $1,465,744  $1,123,839 

Inventories consist of:

 

  

March 31,

2022

  

December 31,

2021

 
         

Raw materials

 $1,368,955  $1,030,955 

Work-in-process

  368,946   194,060 

Inventories

 $1,737,901  $1,225,015 

11

 

 

NOTE 6:         ACCOUNTS RECEIVABLE, NET

 

Accounts receivable are presented net of an allowance for doubtful accounts of approximately $59,000$36,000 and $164,000$59,000 as of September 30, 2021March 31, 2022 and December 31, 2020,2021, respectively. The allowance is based on prior experience and management’s evaluation of the collectability of accounts receivable. Management believes the allowance is adequate. However, future estimates may change based on changes in future economic conditions.

 

 

 

NOTE 7:         LONG-TERM DEBT

 

The Company hashad a loan agreement with HSBC which iswas secured by a mortgage against its Central Islip, NY headquarters.Headquarters. The loan iswas payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity inon March 1, 2022. The balancesbalance as of September 30,December 31, 2021 and December 31, 2020 werewas approximately $1.8 million and $2.1 million respectively.million. Interest accruesaccrued on the loan,Loan, at ourthe Company’s option, at the variable rate of LIBOR plus 1.75% or Prime less 0.5% (1.85% and 1.89%(1.86% atSeptember 30, 2021 and December 31, 2020,2021). respectively). The Company is in compliance with its financial covenant under the mortgage at September 30, 2021.

On November 30, 2017, the Company purchased the premises located at 555 North Research Place, Central Islip, NY (the “555 Building”). The purchase price of the building was $13,850,000 exclusive of closing costs. The Company’s wholly-owned subsidiary, 555 N Research Corporation (the “Assignee”) and the Islip IDA, entered into a Fee and Leasehold Mortgage and Security Agreement (the “Loan”) with HSBC in the amount of $10,387,500, which was usedAccording to finance a portion of the purchase price to acquire the premises located at 555 North Research Place, Central Islip, New York. On July 26, 2021, the Company closed on the sale of the 555 Building and satisfied the loan. (see Note 13)

13

NOTE 7:         LONG-TERM DEBT (continued)

On April 21, 2020, the Company entered into a loan agreement (the “Loan Agreement”) with HSBC Bank USA, National Association pursuant to which the Company was granted a loan in the principal amount of $2,415,970, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted by the United States Congress on March 27, 2020.

The PPP loan, the obligation of which is represented by a note issued by the Company, was to mature on April 21, 2022 and bore interest at a rate of 1% per annum. The note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Under the terms of the PPP, all or a portion ofagreement the Loan may be forgiven, based upon payments made in the firsttwenty-four weeks following receipt of the proceeds, related to payroll costs, continue group health care benefits, utilities and mortgage interest on other debt obligations incurred before February 15, 2020. The Company filed an application for forgiveness in April 2021 andloan was satisfied on June 14, 2021 March 1, 2022.the Company received a notification from its lender that on June 10, 2021 the SBA approved the Company’s PPP Loan forgiveness application and remitted payment to the lender for the entire principal amount of the PPP Loan and accrued interest. As a result, the Company has recognized in the nine months ended September 30, 2021 Gain on Debt Extinguishment in the amount of $2,443,418.

 

 

 

NOTE 8:         STOCK-BASED COMPENSATION EXPENSE

 

The Company recorded as part of general$97,110 and administrative expense, $81,000 and $193,000$50,373 during the three and ninemonths ended September 30, 2021,March 31, 2022 respectively, and during the threeand nine2021, months ended September 30, 2020, $65,000 and $206,000, respectively, for the cost of employee and director services received in exchange for equity instruments based on the grant-date fair value of those instruments. The following table summarizes the compensation expense recorded for the three months ended March 31, 2022 and 2021 related to stock-based compensation.

  

Three months ended March 31,

 
  

2022

  

2021

 
         

Cost of revenue

 $16,029  $0 

Engineering, research and development

 $3,941  $0 

Selling and shipping

 $5,246  $0 

General and administrative

 $71,894  $50,373 
         

Total

 $97,110  $50,373 

 

1412

 

NOTE 8:         STOCK-BASED COMPENSATION EXPENSE (continued)

A summary of the stock option activity related to the 2001 Stock Option Plans, the 2007 Share Incentive Plan and the 2016 Share Incentive Plan for the period from January 1, 20212022 through September 30, 2021March 31, 2022 are as follows:

 

2001 Non-Qualified Stock Option Plan

          
 

Beginning

 

Granted

 

Exercised

 

Canceled

 

Ending

    
 

Balance

 

During

 

During

 

During

 

Balance

    
 

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
 

Number of shares

 7,000  0  0  (7,000) 0  0 

Weighted average exercise price per share

 $7.90  0  0  $7.90  0  0 
 

2007 Share Incentive Plan

                        
 

Beginning

 

Granted

 

Exercised

 

Canceled

 

Ending

     

Beginning

 

Granted

 

Exercised

 

Canceled

 

Ending

    
 

Balance

 

During

 

During

 

During

 

Balance

     

Balance

 

During

 

During

 

During

 

Balance

    
 

Outstanding

 

Period

 

Period

 

Period

 

Outstanding

 

Exercisable

  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
  

Number of shares

 345,000  0  0  0  345,000  325,000  220,000  0  0  0  220,000  220,000 

Weighted average exercise price per share

 $12.33  0  0  0  $12.33  $12.46  $12.56  0  0  0  $12.56  $12.56 
 

2016 Share Incentive Plan

            
 

Beginning

 

Granted

 

Exercised

 

Canceled

 

Ending

    
 

Balance

 

During

 

During

 

During

 

Balance

    
 

Outstanding

 

Period

 

Period

 

Period

 

Outstanding

 

Exercisable

 
 

Number of shares

 65,000  328,500  0  0  393,500  65,000 

Weighted average exercise price per share

 $5.94  $4.13  0  0  $4.43  $5.94 

2016 Share Incentive Plan

                        
  

Beginning

  

Granted

  

Exercised

  

Canceled

  

Ending

     
  

Balance

  

During

  

During

  

During

  

Balance

     
  

Outstanding

  

Period

  

Period

  

Period

  

Outstanding

  

Exercisable

 
                         

Number of shares

  398,500   12,500   0   (2,500)  408,500   65,000 

Weighted average exercise price per share

 $4.43  $4.60   0  $4.01  $4.43  $5.94 

 

For the ninethree months ended September 30, 2021,March 31, 2022, the Company granted 328,50012,500 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the fair value of stock options granted during the ninethree months ended September 30, 2021March 31, 2022 is based upon weighted average assumptions as provided below.

 

 

June 2021 Grant

 

3rd quarter 2021 Grant

 
 

150,000 Stock Options

  

178,500 Stock Options

 

Stock Price

 $4.26  $4.01  $4.60 

Exercise Price

 $4.26  $4.01  $4.60 

Dividend yield

 0% 0% 0%

Expected volatility

 67% 67% 68%

Risk-Free interest rate

 1.35% 1.35% 1.79%

Expected life (in years)

 6.00  6.00  6.00 

The Company has a total of 628,500 outstanding stock options, of which 285,000 were exercisable under the two plans at March 31, 2022.

 

1513

 

NOTE 8:         STOCK-BASED COMPENSATION EXPENSE (continued)

The Company has a total of 738,500 outstanding stock options, of which 390,000 were exercisable under the three plans at September 30, 2021.

 

The following table summarizes information about the outstanding and exercisable options at September 30, 2021.March 31, 2022.

 

      

Options Outstanding

  

Options Exercisable

 
          

Weighted

  

Weighted

          

Weighted

     
          

Average

  

Average

          

Average

     

Exercise

  

Number

  

Remaining

  

Exercise

  

Intrinsic

  

Number

  

Exercise

  

Intrinsic

 

Price Range

  

Outstanding

  

Contractual

  

Price

  

Value

  

Exercisable

  

Price

  

Value

 
$4.00-7.00   373,500   9.6  $4.13  $149,000   45,000  $5.00  $0 
$7.01-10.00   20,000   6.6  $8.07  $0   20,000  $8.07  $0 
$10.01-12.00   220,000   2.1  $10.81  $0   200,000  $10.87  $0 
$12.01-15.00   125,000   .7  $15.00  $0   125,000  $15.00  $0 

      

Options Outstanding

  

Options Exercisable

 
          

Weighted

  

Weighted

          

Weighted

     
          

Average

  

Average

          

Average

     

Exercise

  

Number

  

Remaining

  

Exercise

  

Intrinsic

  

Number

  

Exercise

  

Intrinsic

 

Price Range

  

Outstanding

  

Contractual

  

Price

  

Value

  

Exercisable

  

Price

  

Value

 
$4.00-7.00   388,500   9.1  $4.25  $116,000   45,000  $5.00  $0 
$7.01-10.00   20,000   6.1  $8.07  $0   20,000  $8.07  $0 
$10.01-12.00   120,000   3.3  $10.52  $0   120,000  $10.52  $0 
$12.01-15.00   100,000   .4  $15.00  $0   100,000  $15.00  $0 

 

NaN options were exercised during the ninethree months ended September 30, 2021.March 31, 2022. As of September 30, 2021,March 31, 2022, there was $772,000$693,000 of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 3.63.3 years.

 

Restricted Stock Awards

 

The following table summarizesThere were 0 unvested shares of restricted stock awards forat March 31, 2022 and December 31, 2021. During the ninethree months ended September 30, 2021:March 31, 2022

  

Shares of

Restricted

Stock

  

Weighted

Average Grant

Date Fair

Value

 

Unvested outstanding at December 31, 2020

  0   0 

Granted

  42,800  $4.65 

Vested

  0   0 

Forfeited/Cancelled

  (7,646) $4.90 

Unvested outstanding at September 30, 2021

  35,154  $4.59 

there were 0 grants of restricted stock.

 

The fair valuePursuant to the director compensation plan approved on October 11, 2021, each director is entitled to Director Compensation for an Annual Equity Retainer in the amount of $40,000, to be automatically granted on the date of the outstandingCompany’s annual meeting of shareholders (directors may elect to receive payment in restricted stock, awards will be recorded as stock compensation expense over the vesting period. As of September 30, 2021, there was $37,000 of total unrecognized compensation costs related to restricted stock awards, which is expected to be recognized overoptions or a weighted-average period of .25 years.combination thereof).

 

16

NOTE 8:         STOCK-BASED COMPENSATION EXPENSE (continued)

Restricted Stock Units

The following table summarizes activity related to outstanding restricted stock units for the ninethree months ended September 30, 2021:March 31, 2022:

 

      

Weighted

 
  

Shares of

  

Average Grant

 
  

Restricted

  

Date Fair

 
  

Stock Units

  

Value

 

Unvested outstanding at December 31, 2020

  8,750  $5.00 

Granted

  2,333  $5.36 

Vested

  (5,583) $5.32 

Forfeited/Cancelled

  -  $- - 
         

Unvested outstanding at September 30, 2021

  5,500  $4.83 

      

Weighted

 
  

Shares of

  

Average Grant

 
  

Restricted

  

Date Fair

 
  

Stock Units

  

Value

 

Unvested outstanding at December 31, 2021

  5,500  $4.82 

Granted

  0  $0 

Vested

  (5,500) $4.82 

Forfeited/Cancelled

  0  $0 
         

Unvested outstanding at March 31, 2022

  0  $0 

 

The total fair value of vested restricted stock units was $29,700$3,458 for the ninethree months ended September 30, 2021.March 31, 2022.

The fair value of the outstanding restricted stock units will be recorded as stock compensation expense over the vesting period. As of September 30, 2021,March 31, 2022, there was $10,000 of total0 unrecognized compensation costs related to restricted stock units, which is expected to be recognized over a weighted-average period of .4 years.units.

14

 

 

NOTE 9:         INCOME TAXES

 

As of September 30, 2021March 31, 2022 and December 31, 2020,2021, the Company has provided a full valuation allowance against all of the net deferred tax assets. This was based on management’s assessment, including the last threetwo years of operating losses, that it is more likely than not that the net deferred tax assets may not be realized in the future.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was enacted by the United States Congress. As a result of the enactment of the CARES Act, net operating losses (“NOL’s”) generated in 2018-2020 can now be carried back for five years and resulted in the Company recognizing approximately $1.5 million of a tax benefit, of which $.7$.7 million iswas a receivable at September 30, 2021 and December 31, 2020.2021. This tax receivable was collected in the three months ended March 31, 2022. Management continues to evaluate for potential utilization of the Company’s deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections and timing of orders, and cost containment measures.

 

17

 

NOTE 10:         EARNINGS PER SHARE

 

Basic earnings per share is computed by dividing net earnings available to common shareholders (the numerator) by the weighted average number of common shares outstanding (the denominator) for the period presented. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potentially dilutive common shares had been issued.

 

A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

 

 Three months ended Sept. 30, Nine months ended Sept. 30,  

Three months ended

March 31,

 
 

2021

 

2020

 

2021

 

2020

  

2022

 

2021

 
  

Basic weighted average common shares outstanding

 6,685,599  6,640,228  6,683,407  6,633,694  6,725,042  6,680,130 

Dilutive effect of options and unvested restricted shares

  22,284  0   8,406  0   0  0 

Diluted weighted average shares outstanding

  6,707,883  6,640,228   6,691,813  6,633,694   6,725,042  6,680,130 

15

NOTE 10:         EARNINGS PER SHARE (continued)

 

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and ninemonths ended September 30, 2021March 31, 2022 and 2020,2021, because the effect of their inclusion would be anti-dilutive.

 

  

Three months ended Sept. 30,

  

Nine months ended Sept. 30,

 
  

2021

  

2020

  

2021

  

2020

 
                 

Stock Options

  716,216   417,000   730,094   417,000 
   716,216   417,000   730,094   417,000 

  

Three months ended

March 31,

 
  

2022

  

2021

 
         

Stock Options

  628,500   410,000 
   628,500   410,000 

 

Stock options to purchase 738,500628,500 shares of common stock were outstanding and 390,000285,000 were exercisable during the three and ninemonths ended September 30, 2021.March 31, 2022.

 

The dilutive potential common shares on options is calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options are used to repurchase common stock at market value. The number of shares remaining after the proceeds are exhausted represents the potential dilutive effect of the securities.

 

18

 

NOTE 11:          SEGMENT REPORTING

 

The Company operates through 3three (3) segments: CVD Equipment (“CVD”), Stainless Design Concepts (“SDC”) and CVD Materials (“Materials”). The CVD segment is utilized for chemical vapor deposition equipment manufacturing. SDC is the Company’s ultra-high purity manufacturing division in Saugerties, New York for gas control systems. The Materials segment was established to provide material coatings for aerospace, medical, electronic and other applications. The Company evaluates performance based on several factors, of which the primary financial measure is income or (loss) before taxes.

16

NOTE 11:          SEGMENT REPORTING (continued)

 

The Company’s corporate administration activities are reported in the Eliminations and Unallocated column. These activities primarily include intercompany profit, expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for shares granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees, and interest expense.

 

Three Months Ended September 30,March 31,

(In thousands)

 

              

Eliminations* and

     

2021

 

CVD

  

SDC

  

Materials

  

Unallocated

  

Consolidated

 

Assets

 $27,248  $7,053  $1,655  $2  $35,958 
                     

Revenue

  2,074   1,326   937   (7)  4,330 

Operating (loss) income

  (911)  275   441   (727)  (922)

Pretax (loss) income

  (920)  275   7,373(1)  (727)  6,001 
                     

2020

                    

Assets

 $34,888  $6,202  $5,076  $0  $46,166 
                     

Revenue

  2,308   826   990   (131)  3,993 

Operating loss

  (283)  (111)  (261)  (738)  (1,393)

Pretax loss

  (267)  (111)  (176)  (738)  (1,292)

19

NOTE 11:          SEGMENT REPORTING (continued)

Nine Months Ended September 30,

(In thousands)

              

Eliminations* and

     

2021

 

CVD

  

SDC

  

Materials

  

Unallocated

  

Consolidated

 
                     

Revenue

  5,884   3,314   2,654   (122)  11,730 

Operating (loss) income

  (2,664)  637   828   (2,425)  (3,624)

Pretax (loss) income

  (259)  637   8,014(1)  (2,425)  5,967 
                     

2020

                    
                     

Revenue

  8,686   3,661   1,791   (390)  13,748 

Operating income (loss)

  10   556   (754)  (2,229)  (2,417)

Pretax income (loss)

  10   564   (642)  (2,229)  (2,297)

(1)

The Materials segment includes a gain on the sale of building in the amount of $6,894,109 for the three and nine months ended September 30, 2021.

              

Eliminations* and

     

2022

 

CVD

  

SDC

  

Materials

  

Unallocated

  

Consolidated

 

Assets

 $22,575  $7,756  $1,661  $15  $32,007 
                     

Revenue

  2,827   1,415   458   (44)  4,656 

Operating (loss) income

  (736)  442   (6)  (706)  (1,006)

Pretax (loss) income

  (726)  442   (7)  (706)  (997)
                     

2021

                    

Assets

 $29,659  $6,116  $3,407  $24  $39,206 
                     

Revenue

  2,006   827   629   (96)  3,366 

Operating loss

  (575)  (5)  (110)  (929)  (1,619)

Pretax (loss) income

  (590)  (5)  18   (929)  (1,506)

 

*All elimination entries represent intersegment revenues eliminated in consolidation for external financial reporting.

 

 

NOTE 12:          SIGNIFICANT EVENTS- CORONAVIRUS (COVID-19)

 

The Company has been actively monitoring the coronavirus (COVID-19) outbreak and resulting pandemic and its impact on both the global economic and operating environment and specifically on its impact to the Company, its employees, its operations and its financial condition.  In March 2020, the World Health Organization recognized the COVID-19 outbreak as a pandemic based on the global spread of the disease, the severity of illnesses it causes and its effects on society. In response to the COVID-19 outbreak, the governments of many countries, states, cities and other

geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations, including complete or partial government shutdowns of many schools and businesses, including ourthe Company, and advising or requiring individuals to limit or forego their time outside of their homes. Accordingly, the COVID-19 outbreak (including the impact of the COVID Omicron variant) has severely restricted the level of economic activity in many countries, including the United States, and continues to materially and adversely impact global economic activity.  In particular, the aerospace sector, for which the Company relies on a significant part of its business, has been faced with significant reductions to its business due to lack ofreduced air travel. The Company’stravel which has negatively affected new order levels commencing in the first quarter of 2020,bookings and continuing into the first quarter of 2021 saw substantial reductions, while new orders in the second and third quarter of 2021 were substantially higher at approximately $6.0 and $6.1 million, respectively. These overall reduced order levels havehas materially and adversely affected revenues commencing in our second quarter of 2020. While the financial results for the Company’s revenues to date.

first17

NOTE 12:          quarter of 2020 reflected the initial impact of COVID-SIGNIFICANT EVENTS- CORONAVIRUS (COVID-19 and the year ended December 31, 2020 and firstnine months ended September 30, 2021 reflected a substantial adverse effect, the Company) (continued)

Management is unable to predict the extent of the impact the pandemic will have on itsthe Company’s financial position and operating results for the remainder of2021 and into 2022 due to numerous uncertainties, but the impact could be material during any future period affected either directly or indirectly by this pandemic.  The Company intends to continue to evaluate the various government sponsoredgovernment-sponsored plans and programs put in place in response to the COVID-19 pandemic and further plans to take advantage of any such government benefits reasonably available to it.  Moreover, the Company will continue to monitor developments in that area as new government initiatives are passed.

 

The COVID-19 pandemic has adversely impacted worldwide supply chains and the ability to obtain sufficient amounts of raw materials and component parts such as nickel and integrated circuits. Further, geopolitical developments across Europe and Asia have and may continue to restrict our ability to procure raw materials and components, as well as impact our ability to sell our products into China, Russia and other Eastern European and Asian regions. In addition, disruptions and delays in the ability of the Company’s third party freight carriers to transport these items to the Company’s manufacturing facility also continues to be a challenge. During the third and fourth quarters of 2021, and into 2022, the Company experienced increased costs on certain components as well as delays in supply chain delivery, which has and may continue to impact its ability to recognize revenue and reduce the Company’s gross profit margins, as well as extend our manufacturing lead times and reduce its manufacturing efficiencies. The Company is now placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, the Company is utilizing its in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase. While management has initiated actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time period that the supply chain factors may impact its revenues and profitability.

2018

NOTE 13:          SALE OF 555 BUILDING

In order to increase the Company’s liquidity and to provide necessary working capital to support its on-going business and operations, the Company sold the 555 Building. Management had determined the 555 Building was not needed for business operations, and any remaining elements of the Materials Business would be consolidated into the 355 Building, which management believes can accommodate any needs for the Company’s growth for the foreseeable future.

On March 29, 2021, the Company entered into an agreement with Steel K, LLC for the sale of its 555 Building, and on July 26, 2021 the Company closed on the sale of the 555 Building. The sale price was $24,360,000, subject to adjustment for apportionments, adjustments and credits. A portion of the sale proceeds was used to satisfy the existing mortgage debt on the 555 Building, including interest and fees, in the amount of $9,352,719, as well as various costs related to the closing of the transaction. The Company recognized a gain on the sale of the building in the amount of $6,894,109 and received approximately $14,000,000 in net proceeds.

21

 

 

Item 2.         Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

Except for historical information contained herein, this Managements Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements were based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: competition in the Companys existing and potential future product lines of business; the Companys ability to attract and retain key personnel and employees; the Companys ability to obtain financing on acceptable terms if and when needed; uncertainty as to the Companys future profitability, uncertainty as to the future profitability of acquired businesses or product lines, uncertainty as to any future expansion of the Company, uncertainty as to the Companys ability to adequately obtain raw materials and components from foreign markets in light of geopolitical developments and the effect of the novel coronavirus (COVID-19) on our business and operations (including with respect to supply chain disruptions), and those of our customers, suppliers and other third parties.parties . Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward lookingforward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. Past results are no guaranty of future performance. You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used inwith this Report, the words believes, anticipates, expects, estimates, plans, intends, will and similar expressions are intended to identify forward-looking statements.

19

 

Coronavirus (COVID-19)

 

We have been actively monitoring the coronavirus ("COVID-19") outbreak and its impact globally.  Our primary focus to this point has been to ensure the health and safety of our employees.  To that end, we have adopted social distancing practices where appropriate, implemented travel restrictions, and have taken actions to ensure that our facilities are cleaned and sanitized regularly.  These are novel and challenging times and the magnitude of this crisis is requiring us to consider all options to promote the safety of employees, including, where appropriate, or where required to comply with foreign, national, state or local governmental authority recommendations, guidelines, and/or mandates, the temporary reduction or suspension of work at certain of our locations and production facilities to protect employees and curb the spread of the coronavirus.  All of these actionsfactors have adversely impacted our operating results.  In particular, the aerospace sector, for which we rely on for a significant part of our business, has been faced with significant reductions to its business due to lack ofreduced air travel.travel which has negatively affected new order bookings and has materially and adversely affected the Company’s revenues to date. Due to the timing of the COVID-19 outbreak, our new order levels during the year ended December 31, 2020 and into the first quarter of 2021 have seen continued substantial reductions, while new orders in the second, third, and third quarterfourth quarters of 2021 were substantially higher at approximately $6.0 million, and $6.1 million respectively. These overall reduced order levels have materially and adversely affected revenues commencing$5.2 million, respectively, and new orders in our second quarter of 2020. While the financial results for the Company’s first quarter of 2020 reflected the initial2022 were approximately $4.1 million. Significant geopolitical developments across Europe and Asia have and may continue to restrict our ability to procure raw materials and components such as nickel and integrated circuits, as well as impact of COVID-19,our ability to sell our products into China, Russia and the year ended December 31, 2020other Eastern European and the nine months ended September 30 2021 reflected a substantial adverse effect, we areAsian regions. We continue to be unable to predict the extent of the impact the pandemic will have on our financial position and operating results for the remainder of 2021 and into 2022 due to numerous uncertainties (including the impact of the COVID DeltaOmicron variant), supply chain disruptions, rising costs and the impact on the aerospace sector, but the impact could be material during any future period affected either directly or indirectly by this pandemic.  The longer-term impacts from the pandemic are highly uncertain and cannot be predicted.

 

Executive Level Summary

CVD has continued to serve the advanced materials markets with chemical vapor and thermal process equipment for over 38 years. Our products are used in research and development centers as well as in production environments. We develop, design, manufacture and service a broad range of chemical vapor deposition, gas control and other state-of-the-art process equipment and solutions used in advanced materials and coatings. We serve markets ranging from academic/research initiatives to industrial applications. With the adoption of our technology in these markets we see increased usage of our systems across production environments. Major target markets for our business include advanced nanomaterials, batteries and Silicon Carbide for high power electronics; aerospace gas turbine engines and structural components; medical devices (such as implants); advanced semiconductor devices and Silicon for solar cells; and carbon nanotubes and nanowires. Our Application Laboratory supports the development of new material systems and processes. Our CVD Materials group provides material coating services, process development support and process startup assistance with the focus on enabling tomorrows technologiesTM. Our Mesoscribe product line continues to support the aerospace and defense markets with robust direct write instrumentation. Our CVD Tantaline subsidiary which underwent a restructuring and consolidation in 2021 provides chemical-resistant coating services to many industrial applications.

Based on more than 38 years of experience, we use our capabilities in process development, engineering and vertical manufacturing to transform new applications into mainstream manufacturing solutions. We have built a significant library of design expertise, know-how and innovative solutions to assist our customers in developing these intricate processes and to accelerate their production and commercialization. This library of equipment design solutions, along with our manufacturing and systems integration facilities, allows us to provide application-specific design, process and manufacturing solutions to our customers.

2220

 

To expand our presence into various growth markets, we are developing a line of proprietary standard use products to complement our customized legacy systems. Historically, we manufactured products for research and development on an application-specific basis to meet an individual customer’s specific research and production requirements. Our proprietary systems leverage the technological expertise that we have developed through designing these custom systems into a broader standardized product line. The standard product line is easily configured from a wide range of available options to meet diverse product and budgetary requirements. Manufacturing these standardized systems in higher volumes provides us the flexibility to reduce both the cost and delivery time of our systems. These systems, which we market and sell under the EasyTube® and CVD product lines, are sold to universities, research laboratories, and production companies in the United States and throughout the world.

Sales of our proprietary standard systems, custom systems and process solutions have been driven by our installed customer base, which includes Fortune 500 companies. The performance and success of our products has historically driven repeat orders from existing customers as well as generated business from new customers. Furthermore, with our proprietary solutions and expanded focus on “accelerating the commercialization of tomorrows technologiesTM we have been developing a new customer base in addition to growing with our existing customers. We have generally gained new customers through our industry reputation, as well as limited print advertising and trade show attendance (which has been negatively impacted by COVID-19 in 2020, 2021 and into 2022).

Our core competencies in equipment and software design, manufacturing and process development are used to engineer our finished products and to accelerate the commercialization path of our customer base. Our proprietary real-time software allows for rapid configuration, and provides our customers with enabling tools to understand, optimize and repeatedly control their processes. These factors significantly reduce cost, improve quality and reduce the time it takes between customers’ orders and the shipment of our products. Our Application Laboratory allows customers the option to bring up their process tools in our Application Laboratory and to work collaboratively with our scientists and engineers to optimize process performance.

In 2021 and into 2022 our focus has been on our growth markets, the development of standard product solutions and being able to provide solutions from gas/liquid storage through process and process by-product treatment. This has allowed us to provide increased value to our customers.

Recent2022 Developments

 

In January 2021, we launched our Board of Directors concluded that we needed a change in direction and new leadershipstrategy to evaluate our business strategy and operations, and take timely actions to halt and reversetransition the declinesfocus of the past few years. As such, they appointed Emmanuel Lakios as PresidentCompany to standardized products serving global growth application markets. Our growth opportunities in 2022 are consistent with our strategic plan to address and Chief Executive Officer (previously our Vice-President- Sales and Marketing). We began an intensive analysis of our entire business and operations including the Materials Business. Based upon that analysis we believe our primary focus should be on the core equipment business and that the Materials Business strategy should be revised, with some of its current elements potentially minimized or ceased.  Based upon this analysis, we forecasted continued losses and negative cash flow for our Tantaline product line and as a consequence, we have implemented plans to eliminate further investment in our Tantaline product line, which will result in the avoidance of approximately $1.5-$2.0 million in additional costs. In addition, we recorded an impairment charge of $3.6 million during the fourth quarter and year ended December 31, 2020. Based upon certain decisions and actions currently being reviewed, there may be additional costs to be incurred, inclusive of employee related and lease termination costs estimated at approximately $400,000.

During the third quarter of 2021, we started to experience increased costs on certain components as well as delays in supply chain delivery, which also impacts the timing of revenue recognition as well as manufacturing lead times and efficiencies. We have commenced placing purchase orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase.

In order to increase our liquidity and provide necessary working capital to support our on-going business and operations, we decided to sell the 555 Building in February 2021. We determined the 555 Building was not needed for business operations and that any remaining elements of the Materials Business could be consolidated into the 355 Building, which we believe can accommodate any needs for ourserve growth for the foreseeable future. In April 2021, we completed the move of our Tantaline product line to the 355 Building, while the MesoScribe consolidation into the 355 Building was completed during the third quarter of 2021. All functions of the Tantaline product line have been consolidated into the Denmark office and the United States expenses related to Tantaline have ceased.production markets.

 

2321

 

On March 29, 2021, we entered into an agreement with Steel K, LLC forIn the salefirst three months of our 555 Building,2022, and on July 26, 2021, we closed on the sale of the 555 Building. The sale price was $24,360,000, subject to adjustment for apportionments, adjustments and credits. A portion of the sale proceeds was used to satisfy the existing mortgage debt on the 555 Building, including interest and fees, in the amountmonth of $9,352,719, as well as various costs relatedApril 2022, total Company orders were approximately $4.1 million and $7.2 million, respectively. This $11.3 million year to date total for April 2022 included 14 system orders for Silicon Carbide (“SiC”) growth. There have been twenty (20) systems ordered for our PVT-150 system which has been developed for SiC growth over the closing of the transaction. The Company recognized a gain on the sale of the buildinglast 6 months and planned to ship in 2022. In total there were eighteen (18) CVD systems booked in the amountfirst four months of $6,894,109 and received approximately $14,000,000 in net proceeds resulting in increasing our cash balance at September 30, 2021 to $17,446,000.

2022.

 

Statement of Operations

 

 

Three Months Ended

 

Nine Months Ended

  

Three Months Ended

 
 

September 30,

 

September 30,

  

MARCH 31,

 
 

2021

  

2020

  

2021

  

2020

  

2022

  

2021

 
  

Revenue

 $4,329,459  $3,993,204  $11,729,727  $13,748,448  $4,655,727  $3,365,860 
  

Cost of revenue

  3,595,244   3,557,413   9,831,270   10,775,618   3,886,176   2,921,554 
  

Gross profit

  734,215   435,791   1,898,457   2,972,830   769,551   444,306 
  

Operating expenses

  

Research and development

 138,064  90,227  367,008  300,162 

Engineering, research and development

 310,207  310,954 

Selling and shipping

 220,745  142,306  574,476  439,346  272,679  135,755 

General and administrative

  1,297,730   1,595,911   4,581,008   4,650,067   1,192,653   1,616,384 
  

Total operating expenses

  1,656,539   1,828,444   5,522,492   5,389,575   1,775,539   2,063,093 
  

Operating loss

  (922,324)  (1,392,653)  (3,624,035)  (2,416,745)  (1,005,988)  (1,618,787)
  

Other income (expense):

  

Interest income

 1,776  30,348  3,402  60,728  18,282  1,223 

Interest expense

 (35,973) (104,041) (250,194) (336,107) (9,634) (107,221)

Gain on Sale of Building

 6,894,109  -  6,894,109  - 

Gain on Debt Extinguishment

 -  -  2,443,418  - 

Other Income

  63,143   174,705   499,970   394,938   -   219,235 

Total other income, net

  6,923,055   101,012   9,590,705   119,559   8,648   113,237 
  

Income (loss) before income tax

 6,000,731  (1,291,641) 5,966,670  (2,297,186)

Loss before income tax

 (997,340) (1,505,550)
  

Income tax expense (benefit)

  27,327   -   28,391   (1,529,595)

Income tax expense

  -   - 
  

Net income (loss)

 $5,973,404  $(1,291,641) $5,938,279  $(767,591)

Net loss

 $(997,340) $(1,505,550)

 

2422

 

Three Months Ended September 30,March 31, 2022 vs. March 31, 2021 vs. September 30, 2020

 

Revenue

 

Our revenue for the three months ended September 30, 2021March 31, 2022 was $4.3$4.7 million compared to $4.0$3.4 million for the three months ended September 30, 2020,March 31, 2021, an increase of $.3$1.3 million or 8.4%38.3%. Despite achieving this modest sales increase, overall sales levels continue to be negatively affected. This is primarily attributable to the impacts of COVID-19 which significantly reduced the Company’s orders commencing in the first quarter of 2020, for the year ended December 31, 2020 and into the first quarter of 2021, which in turn significantly decreased our revenues in the subsequent quarters. In addition, we have had delays, and continue to experience delays in our supply chain delivery of components which hampers our ability to recognize revenue more timely. The increase in revenue for the three months ended September 30, 2021March 31, 2022 versus the prior year’syear period was primarily attributable to increased revenue of $.5$.8 million from the CVD Equipment segment related to spare parts and equipment sales, $.6 million from our SDC segment, offset, in part by, decreased revenue of $.2$.1 million from the CVD Equipment segment related to spare parts and equipment sales. New orders for theMaterials segment. Despite achieving a sales increase of $1.3 million or 38.3% this quarter, ended September 30, 2021 were approximately $6.1 million and improved as compared to $6.0 millionthe prior year quarter, overall sales levels continue to be negatively affected, primarily attributable to the impacts of COVID-19 including delays in our supply chain delivery of components which impacts our ability to recognize revenue more timely. However, as a result of increased new orders, primarily in the prior quarter ended June 30,last three quarters of 2021, andthe result of a recovery in the marketplace, exclusive of aerospace, as well as the execution of our operating plan, we have achieved four sequential quarters of revenue increases during 2021. Quarterly revenue in 2021 was $3.4 million, $4.0 million, $4.3 million and $4.7 million, during Q1 to Q4, respectively, and revenue in Q1 2022 was essentially unchanged at $4.7 million. Our backlog at March 31, 2022 was approximately $9.9 million, a decrease of $.5 million as compared to December 31, 2021 of $10.4 million. This decrease is due to the quartertiming of new orders in Q1 2022 of $4.1 million, as compared to revenue of $4.7 million. While aerospace sales had represented as much as 60% of our total revenue, during the three months ended September 30, 2020.March 31, 2022 and 2021 it represented approximately 15.1% and 21.2%, respectively. This is due to the negative effect the COVID-19 crisis has had initially in 2020 and continuing to date on the aerospace sector, which resulted from reduced travel and reduction of industry gas turbine engine sales.

 

The revenue contributed by the CVD Equipment segment for the three months ended September 30, 2021March 31, 2022 was $2.1$2.8 million, which totaled 47.9%60.7% of our overall revenue, and was (10.2%)40.8% or ($.2 million) lower$.8 million higher than the segment’s $2.3$2.0 million contribution made in the three months ended September 30, 2020,March 31, 2021, which totaled 57.8%59.6% of our overall revenue. This revenue decreaseincrease is the result of a decreaseincreases of $.4 million in spare parts sales, which continue to be impacted by the slow down in aerospace demand due to COVID-19, offset, in part by, and an increase of $.2$.4 million from equipment sales.

 

Revenue for our SDC segment was $1.3$1.4 million for the three months ended September 30, 2021March 31, 2022 as compared to $.8 million for the three months ended September 30, 2020,March 31, 2021, an increase of $.5$.6 million resulting from the receipt of one large order in 2021,2022, compared to 2020.2021.

 

Revenues for our CVD Materials segment were $.9$.5 million for each of the three months ended September 30, 2021 and 2020.March 31, 2022, as compared to $.6 million in the three months ended March 31, 2021.

23

 

Gross Profit

 

Gross profit for the three months ended September 30, 2021 amountedMarch 31, 2022 was to $.7$.8 million, with a gross profit margin of 17.0%16.5%, as compared to a gross profit of $.4 million and a gross profit margin of 10.9%13.2% for the three months ended September 30, 2020.March 31, 2021. The increase in gross profit and gross profit margin was primarily the result of improved manufacturing efficiencies, and product mix, and to a lesser extent, leveraging fixed costs on higher sales levels, and product mix, which more than offset certain component cost increases.increases and compensation costs. During the quarter ended September 30, 2021, we started to experience increased costs on certain components as well as delays in supply chain delivery, which also impacts revenue as well as manufacturing lead times and efficiencies. We have begunbeen placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase.increases. In late 2021, we initiated price increases on new quotations which we anticipate will mitigate our cost increases and we anticipate will benefit margins during 2022.

 

25

Research and Development, Selling and General and Administrative Expenses

 

Engineering, Research and Development

 

DueFor the three months ended March 31 2022 and 2021, engineering, research and development expenses were $310,207 and $310,954, respectively, essentially unchanged. General engineering support and expenses related to focusing development on more standard products and value added development are reflected as engineering, research and development, while due to the technical development required on our custom orders, our research and developmentengineering team and their expenses are charged to costs of goods sold when they are working directly on a customer project. When they are not working on a customer project, they work in our Application Laboratory and their costs are charged to research and development. For the three months ended September 30, 2021 and 2020, our research and development expenses totaled $138,000 and $90,000, respectively, an increase of $48,000 related to focusing development on more standard products and value added development.

 

Selling

 

Selling expenses were $221,000$272,679 or 5.1%5.9% of the revenue for the three months ended September 30, 2021March 31, 2022 as compared to $142,000$135,755 or 3.5%4.0% of the revenue for the three months ended September 30, 2020.March 31, 2021. The increase in 20212022 was primarily the result of increased employee compensation, includingwhich includes the transfer of one employee from administration to focus on all sales and marketing initiatives, which is now in line with ongoing expectations, and benefit costs during the three months ended September 30, 2021,March 31, 2022, as compared to September 30, 2020.March 31, 2021.  

 

General and Administrative

 

General and administrative expenses for the three months ended September 30, 2021March 31, 2022 were $1.3 million$1,192,653 or 30.0%25.6% of revenue as compared to $1.6 million$1,616,384 or 40.0%48.0% of revenue for the three months ended September 30, 2020, anMarch 31, 2021, a decrease of $.3 million.$423,731 or 26.2%. The decrease in these expenses is primarily due to a reductionreduced legal expenses of $206,000 due to higher costs in employeesthe three months ended March 31, 2021 related to governance and employee related costs of $132,000, reduced costs of $101,000 for real estate taxes and utilitiesstrategic planning activities, including $75,000 related to the preparation of the sale of the 555 Building soldbuilding which closed in July 2021, as well as less depreciation expense, primarily2021. In addition, other operating costs decreased due to the 555 Building in the amountlower building operating costs as a result of $133,000, and a reduction of bad debt expense of $40,000, offset, in part by, increased legal costs of $92,000, of which $33,000 related to the sale of the 555 Building in July 2021, and the balance was related to general corporate governance, employee related matters and intellectual property matters, and increased shareholder relations costsconsolidation of $42,000.our facilities into our 355 facility.

24

 

Operating loss

 

As a result of increased sales and the increased gross profit margins of $.3 million, and reduced operating expenses of $.2$.3 million, our operating loss was $.91.0 million in the three months ended September 30 2021,March 31 2022, compared with an operating loss of $1.4$1.6 million in the three months ended September 30, 2020.March 31, 2021.

26

 

Other income (expenses)

 

Other income (expenses) was $6,923,000$8,648 and $101,000$113,237 for the three months ended September 30,March 31, 2022 and 2021, and 2020, respectively. On July 26, 2021, we sold our 555 building and recognized a gain on the sale in the amount of $6,894,109. Other income from subleasing a portion of our then 555 Building (which was $63,000 and $175,000sold on July 26, 2021) was $219,235 for the three months ended March 31, 2021 as compared to none in the three months ended September 30, 2021 and 2020, respectively. The decrease of $112,000 was theMarch 31, 2022. As a result of no longer receiving rental income uponour increased cash position from the sale of the 555 Building. As a result of lower interest rates,Building in July 2021, interest income decreased $28,000,increased $17,059, to $2,000$18,282 for the three months ended September 30, 2021March 31, 2022 as compared to $30,000$1,223 in 2020.2021. In addition, interest expense related to the Company’s mortgages decreased $68,000$97,587 to $36,000$9,634 in the three months ended September 30, 2021,March 31, 2022, as compared to $104,000$107,221 in 2020,2021, the result of our 555 Building mortgage satisfied on July 26, 2021.2021, as well as the satisfaction of our remaining mortgage on the 355 building on March 1, 2022.

 

Income Taxes

 

Income tax expense for the three months ended September 30,March 31, 2022 and 2021, and 2020, were $27,000 and $0, respectively. The tax expense for the three months ended 2021 related the gain on the sale of the building, which were reduced by the benefit of our net operating loss carryforwards. We continue to evaluate for potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections and timing of orders, cost containment measures and other factors.

 

Net income (loss)loss

 

As a result of the foregoing factors, including the effect of recognizing the $6.9 million gain on the sale of our 555 Building, we reported a net incomeloss of $6.0 million,$997,340 or $0.89$0.15 per basic and diluted share, for the three months ended September 30, 2021,March 31, 2022, as compared to a net loss of ($1.3) million,$1,505,550, or ($0.19)$0.23 per basic and diluted share for the three months ended September 30, 2020.

Nine Months Ended September 30, 2021 vs. September 30, 2020

Revenue

Our revenue for the nine months ended September 30, 2021 was $11.7 million as compared to $13.7 million for the nine months ended September 30, 2020, a decrease of $2.0 million or 14.7%. This revenue reduction is primarily attributable to the impacts of COVID-19 which significantly reduced the Company’s order levels commencing in the first quarter of 2020, for the year ended DecemberMarch 31, 2020 and into the first quarter of 2021, (while new orders in the second and third quarter of 2021 where substantially higher at approximately $6.0 million and $6.1 million, respectively). This in turn significantly decreased our revenues in the subsequent quarters. The decrease was primarily attributable to decreased revenue of $2.8 million from our CVD Equipment segment related to spare parts and equipment sales and $.2 million decrease in our SDC segment, offset, in part by, an increase of $1.0 million in our CVD Materials segment.

27

The revenue contributed for the nine months ended September 30, 2021 by the CVD Equipment segment was $5.9 million, which totaled 50.2% of our overall revenue, was (32.3%) or ($2.8 million) lower than the segment’s $8.7 million contribution made in the nine months ended September 30, 2020, which totaled 63.2% of our overall revenue. This net revenue reduction is the result of a decrease of $3.3 million from spare part sales impacted by the slow down in aerospace demand due to COVID-19, offset, in part by, an increase of $.5 million from equipment sales.

Revenue for our SDC segment was $3.2 million for the nine months ended September 30, 2021 as compared to $3.5 million for the nine months ended September 30, 2020, a decrease of $.3 million.

Revenues for our CVD Materials segment were $2.6 million for the nine months ended September 30, 2021 as compared to $1.6 million for the nine months ended September 30, 2020. This increase of $1.0 million was the result of increased Tantaline® related revenue of $.8 million, primarily from the Company’s Denmark operations, and increased MesoScribe product revenue of $.2 million, both the result of improvement in new order rates.

Gross Profit

Gross profit for the nine months ended September 30, 2021 amounted to $1.9 million, with a gross profit margin of 16.2%, as compared to a gross profit of $3.0 million and a gross profit margin of 21.6% for the nine months ended September 30, 2020. The reduction in gross profit and gross profit margin, was primarily the result of the impact of $2.0 million in decreased sales as a result of the impact of COVID-19, and the impact of fixed costs and payroll to support higher sales levels, offset in part by reduced employee payroll and related costs commencing in the nine months ended September 30, 2020 as a result of the COVID-19 mandates imposed.

Research and Development, Selling and General and Administrative Expenses

Research and Development

Due to the technical development required on our custom orders, our research and development team and their expenses are charged to costs of goods sold when they are working directly on a customer project. When they are not working on a customer project, they work in our Application Laboratory and their costs are charged to research and development. For the nine months ended September 30, 2021 and 2020, our research and development expenses totaled $367,000 and $300,000, respectively, an increase of $67,000, related to focusing development on more standard products and value added development.

28

Selling

Selling expenses were $575,000 or 4.9% of the revenue for the nine months ended September 30, 2021 as compared to $439,000 or 3.2% of the revenue for the nine months ended September 30, 2020. The increase in 2021 was primarily the result of the impact of reduced employee and employee related costs, during the nine months ended September 30, 2020, due to the COVID-19 related mandates, while with our return to operating normalcy, we expanded our focus in customer account engagement in 2021 which resulted in increased personnel and travel related costs, as well as the transfer of one employee from administration during 2021 to focus on sales and marketing initiatives.  

General and Administrative

General and administrative expenses for the nine months ended September 30, 2021 were $4.6 million or 39.1% of revenue compared to $4.7 million or 33.8% of revenue for the nine months ended September 30, 2020, a decrease of $.1 million. The decrease in these expenses is primarily due to reduction in employees and employee-related costs of $259,000, recovery of bad debts of $225,000, less depreciation primarily due to the 555 Building in the amount of $318,000, and lower insurance and general office expenses of $100,000, offset, in part by, costs to vacate the 555 Building and prepare the 355 Building for the consolidation of operations in the amount of $232,000, related to personnel costs and outside services, increased legal costs of $518,000, of which $135,000 related to the preparation of the sale of the 555 Building, and the balance was related to general corporate governance, employee related matters and intellectual property, and increased shareholder relations costs of $99,000 due the timing of the shareholder meeting as well as additional efforts.

Operating loss

Primarily the result of substantially lower sales and the reduction in gross profit margins, our operating loss was $3.6 million in the nine months ended September 30, 2021, compared with an operating loss of $2.4 million in the nine months ended September 30, 2020.

Other income (expenses)

Other income (expenses) was $9,591,000 and $120,000 for the nine months ended September 30, 2021 and 2020, respectively. On July 26, 2021, we sold our 555 building and recognized a gain on the sale in the amount of $6,894,109. Gain on debt extinguishment was $2,443,000 and $0 for the nine months ended September 30, 2021 and 2020, respectively, the result of forgiveness of debt income from the Company’s PPP loan in the amount of $2,443,000 in the nine months ended September 30, 2021. Other income from subleasing a portion of our 555 Building was $500,000 and $395,000 in the nine months ended September 30, 2021 and 2020, respectively. The increase of $105,000 was the result of higher rent due to increased occupancy in 2021, until the sale of the Building which occurred on July 26, 2021. As a result of lower interest rates, interest income decreased $58,000, to $3,000 for the nine months ended September 30, 2021 as compared to $61,000 in 2020. In addition, interest expense related to our mortgages decreased $86,000 to $250,000 for the nine months ended September 30, 2021, as compared to $336,000 in 2020, the result of our 555 Building mortgage satisfied on July 26, 2021.

29

Income Taxes

For the nine months ended September 30, 2021, there was a $28,000 income tax expense related to the gain on the sale of the building, which were reduced by the benefit of our net operating loss carryforwards, as compared to an income tax benefit of $1.5 million for the nine months ended September 30, 2020. On March 27, 2020, the CARES Act was enacted by the United States Congress. As a result of the enactment of the CARES Act, net operating losses (“NOL’s”) generated in 2018-2020 can now be carried back for five years and resulted in the Company recognizing approximately $1.5 million of a tax receivable. We continue to evaluate the potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, reviewing our economic models, including projections and timing of orders, cost containment measures and other factors.

Net (loss) income

As a result of the foregoing factors, including the effect of recognizing a $6.9 million gain on the sale of our 555 Building and $2.4 million in forgiveness of debt income related to the Company’s PPP Loan, we reported net income of $5.9 million, or $0.89 per diluted share, for the nine months ended September 30, 2021, as compared to a net loss of ($.8 million) (which included the $1.5 million tax benefit as noted above), or $0.12 per diluted share for the nine months ended September 30, 2020.

 

 

Liquidity and Capital Resources

 

As of September 30, 2021,March 31, 2022, we had aggregate working capital of $17.7$15.9 million compared to aggregate working capital of $8.1$16.7 million at December 31, 2020.2021. Our cash and cash equivalents at September 30, 2021March 31, 2022 and December 31, 20202021 were $17.4$13.3 million and $7.7$16.7 million, respectively.

 

Net cash used in operating activities was $3.6$1.4 million. This is the result of a net loss, adjusted for non-cash items, of $2.6$.6 million, decreased contract liabilities of $.9 million, increased inventory of $.5 million to support increased orders and attempt to mitigate further supply chain impacts, increased contract assets of $1.1 million, increased accounts receivable of $.8, increased inventory of $.3$.2 million, offset, in part by, increased contract liabilities ofdecreased tax receivables $.7 million and decreased other assetsincreased accrued expenses of $.5$.1 million.

In order to increase our liquidity and to provide necessary working capital to support our on-going business and operations, on July 26, 2021 we closed on the sale of the 555 Building. The sale price was $24,360,000, subject to adjustment for apportionments, adjustments and credits. A portion of the sale proceeds was used to satisfy the existing mortgage debt on the 555 Building, including interest and fees, in the amount of $9,352,719, as well as various costs related to the closing of the transaction. We recognized a gain on the sale of the building in the amount of $6,894,109 and received approximately $14,000,000 in net proceeds.

 

3025

 

Long term debt during the period decreased by $9.5Capital expenditures for equipment were $.2 million from principal payments on our mortgages in Central Islip, NY. This included the principal repayment in the amount of approximately $9.1 million, to satisfy our loan at closing of the sale of the 555 Building.

Capital expenditures were $213,000 in the ninethree months ended September 30, 2021 related primarily to improvements to the 355 Building related to moving the Company’s operations from the 555 Building facility.March 31, 2022.

 

We havehad a loan agreement with HSBC USA, N.A. (the “HSBC”) which iswas secured by a mortgage on our Central Islip headquarters at 355 South Technology Drive. The loan iswas payable in 120 consecutive equal monthly installments of $25,000 in principal plus interest and a final balloon payment upon maturity in March 2022. The balances as of September 30, 2021 and December 31, 2020 were approximately $1.8 million and $2.1 million respectively. Interest accrues on the loan, at our option, at the variable rate of LIBOR plus 1.75% or Prime less 0.5% (1.85% and 1.89% at September 30, 2021 and December 31, 2020, respectively).

On August 5, 2019, we entered into a Mortgage Modification Agreement which replaced the former covenant with a Minimum Liquid Assets (“MLC”) covenant, and on October 22, 2020, we entered into a Second Mortgage Modification Agreement modifying certain MLC balances. We were in compliance with our financial covenant under the mortgage at September 30, 2021.

Due to the effects of the COVID-19 pandemic, on April 21, 2020, we entered into a loan agreement (the “Loan Agreement”) with HSBC Bank USA, National Association pursuant to which we were granted a loan in the principal amount of $2,415,970, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted by the United States Congress on March 27, 2020.

The PPP loan, the obligation of which is represented by a note issued by us, was1, 2022. According to mature on April 21, 2022 and bore interest at a rate of 1% per annum. The note may be prepaid at any time prior to maturity with no prepayment penalties. Under the terms of the PPP,agreement the loan was satisfied on March 1 2022 resulting in total debt repayments of $1.8 million during the three months ended March 31, 2022.

The COVID-19 outbreak has resulted in extended shutdowns of certain businesses in United States and around the world. We have been actively monitoring the COVID-19 outbreak and its impact globally.  Our primary focus to this point has been to ensure the health and safety of our employees.  To that end, we have adopted social distancing where appropriate, implemented travel restrictions, and we have taken actions to ensure that locations and facilities are cleaned and sanitized regularly.  These are novel and challenging times and the magnitude of this crisis is requiring us to consider all options to promote the safety of employees, including, where appropriate, or a portionwhere required to comply with foreign, national, state or local governmental authority recommendations, guidelines, and/or mandates, the temporary reduction or suspension of work at certain of the Loan mayCompany’s locations and production facilities to protect employees and curb the spread of the coronavirus.  All of these actions have adversely impacted our operating results.  In particular, our aerospace sector, for which we rely on a significant part of our business, has been faced with significant reductions to its business due to reduced air travel which has negatively affected new order bookings and has materially and adversely affected the Company’s revenues to date. We continue to be forgiven, basedunable to predict the extent of the impact the pandemic will have on our financial position and operating results for the remainder of 2022 due to numerous uncertainties (including the impact of the COVID Omicron variant), supply chain disruptions, rising costs and the impact on the aerospace sector, but the impact could be material during any future period affected either directly or indirectly by this pandemic.  The longer-term impacts from the pandemic are highly uncertain and cannot be predicted. Our return to profitability is dependent upon, payments madeamong other things, the receipt of new equipment orders, the lessening of the ongoing effects of COVID-19 on our business and the Aerospace market, improvement in the first twenty-four weeks following receiptoperations of the proceeds, related to payroll costs, continue group health care benefits, utilitiesmaterials business, as well as managing planned capital expenditures and mortgage interest on other debt obligations incurred before February 15, 2020. The Company filed an application for forgiveness in April 2021 and on June 14, 2021 the Company received a notification from its lender that on June 10, 2021 the SBA approved the Company’s PPP Loan forgiveness application and remitted payment to the lender for the entire principal amount of the PPP Loan and accrued interest. As a result, the Company has recognized in the nine months ended September 30, 2021 forgiveness of debt income in the amount of $2,443,418.operating expenses.

 

As a result of the March 27, 2020 CARES Act enactment allowing the carryback of NOL’s five years, we recognized a $1.5 million tax benefit. We have collected $.8 million in the year ended December 31, 2020, and as of September 30, 2021 there remains a receivable in the amount of $.7 million.

 

Based upon all of these factors, we believe that our cash and cash equivalent positions and our projected cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve to eighteen months of the filing of this Form 10-Q. Should the current environment continue longer or worsen, we will continue to assess our operations and take actions anticipated to maintain our operating cash to support the working capital needs, as well as compliance with our loan covenant.needs.

 

3126

 

Off-Balance Sheet Arrangements.

 

We have no off-balance sheet arrangements at this time.

 

 

Item 3.                           Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4.                           Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 13d-15(e) under the Exchange Act of 1934, as amended, (the “Exchange Act”)). As required by Rule 13a-15(b) under the Exchange Act, our management, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q (the “Report”).

 

Based on that review and evaluation, our Chief Executive Officer and Chief Financial Officer, along with others in our management, have determined that as of the end of the period covered by this Report on Form 10-Q the disclosure controls and procedures were effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosures.

 

Changes in Internal Controls

 

There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.

 

Limitations on the Effectiveness of Controls

 

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 

3227

 

CVD EQUIPMENT CORPORATION

 

PART II

 

OTHER INFORMATION

 

 

Item 1.

Legal Proceedings.

None.
Item 1A.Risk Factors.

 

The following risk factor is in addition to the risk factors previously disclosed in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 31, 2021. The risk factor set forth below should be read in conjunction with the risk factors section and the Management's Discussion and Analysis section included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 31, 2021.None.

 

Supply chain delays and cost increases may adversely affect our business.

Item 1A.

Risk Factors.

 

The COVID-19 pandemic has adversely impacted worldwide supply chains and the ability to obtain sufficient amounts of component parts. In addition, disruptions and delays in the ability of our third party freight carriers to transport these items to our manufacturing facility also continues to be a challenge. During Q3 2021, we experienced increased costs on certain components as well as delays in supply chain delivery, which may also impact our ability to recognize revenue and reduce our gross profit margins, as well as extend our manufacturing lead times and reduce our manufacturing efficiencies. We have commenced placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase. While we have initiated actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time period that the supply chain factors may impact our revenues and profitability.

Except as noted above, thereThere have been no other material changes to the risk factors disclosed in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 31, 2021.2022.

 

33

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

None.

Item 3.

Defaults Upon Senior Securities.

None.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.         

Not applicable.

Item 5.

Other Information.

None.

None.

Item 6.

Exhibits

31.1*

31.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated November 15, 2021May 16, 2022

 

31.2*

Certification of Thomas McNeill, Chief Financial Officer, dated November 15, 2021May 16, 2022

 

32.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated November 15, 2021,May 16, 2022, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

28

32.2*

32.2*

Certification of Thomas McNeill, Chief Financial Officer, dated November 15, 2021,May 16, 2022, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101.1**

Inline XBRL Instance.

 

101.SCH**

Inline XBRL Taxonomy Extension Schema.

 

101.CAL**

Inline XBRL Taxonomy Extension Calculation.

 

101.DEF**

Inline XBRL Taxonomy Extension Definition.

 

101.LAB**

Inline XBRL Taxonomy Extension Labels.

 

101.PRE**

Inline XBRL Taxonomy Extension Presentation.

 

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

________________

* Filed herewith.

 

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not to be filed or part of a registration statement of prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

 

3429

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 1516th day of November 2021.May 2022.

 

CVD EQUIPMENT CORPORATION

By

/s/ Emmanuel Lakios

By:

/s/ Emmanuel Lakios

Emmanuel Lakios

President and Chief Executive Officer

 

(Principal Executive Officer)

   
 

By:

/s/ Thomas McNeill
 

Thomas McNeill

Executive Vice President and

Chief Financial Officer

(Principal Financial and

  Thomas McNeill
Executive Vice President and
Chief Financial Officer
(Principal Financial and

Accounting Officer)

 


 

EXHIBIT INDEX

 

 

31.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated November 15, 2021May 16, 2022

 

31.2*

Certification of Thomas McNeill, Chief Financial Officer, dated November 15, 2021May 16, 2022

 

32.1*

Certification of Emmanuel Lakios, Chief Executive Officer, dated November 15, 2021,May 16, 2022, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

32.2*

Certification of Thomas McNeill, Chief Financial Officer, dated November 15, 2021,May 16, 2022, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101.1**

Inline XBRL Instance.

 

101.SCH**

Inline XBRL Taxonomy Extension Schema.

 

101.CAL**

Inline XBRL Taxonomy Extension Calculation.

 

101.DEF**

Inline XBRL Taxonomy Extension Definition.

 

101.LAB**

Inline XBRL Taxonomy Extension Labels.

 

101.PRE**

Inline XBRL Taxonomy Extension Presentation.

 

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

________________

* Filed herewith.

 

** Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not to be filed or part of a registration statement of prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

 

3631